Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD of BI 655130 in Healthy Males
NCT02852824Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Aug 2016
- Primary completion
- Aug 2017
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in generalized pustular psoriasis (GPP) comparing BI 655130 (spesolimab) with Placebo (2 arms). Primary endpoint: Percentage of Subjects With Drug-related Adverse Events up to 179 days. Started Aug 2016; status: completed.
02
Drugs
spesolimab
03
Conditions
generalized pustular psoriasis (GPP)
Beyond the preview
Go deeper on NCT02852824.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02852824.